Media stories about Chemours (NYSE:CC) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Chemours earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave news stories about the specialty chemicals company an impact score of 46.6331421027877 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:
- Reviewing Albemarle (ALB) and Chemours (CC) (americanbankingnews.com)
- Chemours Co (CC) Receives Average Recommendation of “Buy” from Analysts (americanbankingnews.com)
- Insider Selling: Chemours Co (CC) VP Sells 29,381 Shares of Stock (americanbankingnews.com)
- Head to Head Survey: Taminco (TAM) & Chemours (CC) (americanbankingnews.com)
Shares of Chemours (NYSE:CC) traded down $0.02 on Wednesday, hitting $49.96. 345,486 shares of the company’s stock were exchanged, compared to its average volume of 1,789,064. Chemours has a 1-year low of $32.31 and a 1-year high of $58.08. The firm has a market capitalization of $9,190.00 and a PE ratio of 9.57. The company has a current ratio of 2.12, a quick ratio of 1.55 and a debt-to-equity ratio of 4.74.
Chemours (NYSE:CC) last announced its quarterly earnings results on Wednesday, February 14th. The specialty chemicals company reported $1.19 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.24. The business had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.55 billion. Chemours had a net margin of 12.06% and a return on equity of 115.54%. The business’s revenue for the quarter was up 19.1% on a year-over-year basis. During the same period last year, the business earned $0.08 earnings per share. equities analysts forecast that Chemours will post 5.3 earnings per share for the current year.
Chemours declared that its Board of Directors has authorized a share repurchase plan on Friday, December 1st that allows the company to repurchase $500.00 million in shares. This repurchase authorization allows the specialty chemicals company to buy shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board believes its stock is undervalued.
Several analysts recently commented on the stock. Goldman Sachs Group lowered shares of Chemours from a “buy” rating to a “neutral” rating and set a $55.00 price target on the stock. in a research report on Wednesday, December 6th. Zacks Investment Research downgraded shares of Chemours from a “buy” rating to a “hold” rating in a report on Wednesday, December 6th. Jefferies Group increased their price objective on shares of Chemours to $66.00 and gave the company a “buy” rating in a report on Monday, December 4th. Morgan Stanley started coverage on shares of Chemours in a report on Tuesday, January 30th. They set an “equal weight” rating and a $57.50 price objective on the stock. Finally, Barclays reissued a “buy” rating and issued a $60.00 price target on shares of Chemours in a research note on Wednesday, December 6th. Three investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $57.95.
In other news, insider Paul Kirsch sold 13,770 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $50.01, for a total transaction of $688,637.70. Following the completion of the sale, the insider now owns 63,093 shares in the company, valued at approximately $3,155,280.93. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Mark Newman sold 29,381 shares of the business’s stock in a transaction that occurred on Friday, March 9th. The stock was sold at an average price of $49.19, for a total transaction of $1,445,251.39. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was posted by Equities Focus and is the sole property of of Equities Focus. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.equitiesfocus.com/2018/03/14/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-chemours-cc-share-price.html.
Chemours Company Profile
The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.